Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Shanghai Institute of Pharmaceutical Industry

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

China State Institute of Pharmaceutical Industry

Meng Guo

Mingtong Hu

Yinsheng Zhang

Xueyan Zhu

Wangwei Ao

Wei Wu

Yu Huang

Li Zhu

Ling Yang

Hongjiang Xu

Yong Peng

Yongxin Han

Hong Luo

Yuandong Hu

Shanchun Wang

Zhedong Yuan

Hanbin Shan

Yanqing Yang

Yinghui Sun

Xiong Yu

Fansheng Kong

Liguang Dai

Hubo Wang

Xiaowei Duan

Yuan Li

Jie Wu

Yajun Guo

Pujun Wang

Jiasong Zhang

Jiude Sun

Duzheng Wang

Zhaobai Zhong

Yin Lu

Disclosed are a crystalline form of a five-membered N heterocyclic compound, particularly, a crystalline form of a compound as represented by formula I, and an application of the crystalline form in preparation of a medication for preventing or treating a disease benefiting from inhibition of capsid protein assembly.

Crystal form of five-membered n heterocyclic compound, and application thereof

Disclosed by the present application is a crystalline form of a capsid protein assembly inhibitor containing an N hetero five-membered ring; specifically disclosed is the crystalline form of the compound of formula I; also comprised is an the application of said crystalline form in the preparation of a drug for preventing or treating diseases benefiting from the inhibition of capsid protein assembly.

Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals. 

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

The present invention relates to a nintedanib diethanesulfonate salt A-type crystal represented by formula (II), and also relates to a crystalline composition and pharmaceutical composition comprising the crystal, and preparation method and use thereof. An X-ray powder diffraction spectrum of the nintedanib diethanesulfonate salt A-type crystal of the present invention has a diffraction peak at about 14.64, 18.79, 19.31, 20.11, 21.20, 22.45 and 26.71&#xb0; when represented via a 2&#x3b8; value. The nintedanib diethanesulfonate salt A-type crystal of the present invention has a stable property, is non-hygroscopic and difficult to degrade, and is particularly suitable for medicine production. 

Nintedanib diethanesulfonate salt crystal and preparation method and use thereof

Disclosed are a method for preparing a dabigatran etexilate intermediate, and an intermediate compound. The method for preparing a dabigatran etexilate intermediate 4 comprises: reacting a compound 3 with a C-Calkyl alcohol solution of methylamine in an organic solvent, wherein, X=chlorine, bromine, or iodine. Also disclosed are an intermediate compound 3 and a preparation method thereof. The method for preparing a dabigatran etexilate intermediate of the present invention has the advantages of simple process, easy operation, high yield, and easy purification, thus being suitable for industrial production. 

Method for preparing dabigatran etexilate intermediate, and intermediate compound

Growing community of inventors

Lianyungang, China

Meng Guo